Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5322 ARTÍCULOS , VIENDO DEL 4891 AL 4905

Therapeutic intervention with virtual reality in patients with Parkinson's disease for upper limb motor training: A systematic review

Fernández-González D, Rodriguez-Costa I, Sanz-Esteban I, Estrada-Barranco C.

Rehabilitacion (Madr). 2023 Apr-Jun;57(2):100751. doi: 10.1016/j.rh.2022.06.003. Epub 2022 Nov 4.

Deep Brain Stimulation-Withdrawal Syndrome in Parkinson's Disease: Risk Factors and Pathophysiological Hypotheses of a Life-Threatening Emergency

Grimaldi S, Eusebio A, Carron R, Regis JM, Velly L, Azulay JP, Witjas T.

Neuromodulation. 2023 Feb;26(2):424-434. doi: 10.1016/j.neurom.2022.09.008. Epub 2022 Nov 4.

Rehabilitating Cough Dysfunction in Parkinson's Disease: A Randomized Controlled Trial

Troche MS, Curtis JA, Sevitz JS, Dakin AE, Perry SE, Borders JC, Grande AA, Mou Y, Vanegas-Arroyave N, Hegland KW.

Mov Disord. 2023 Feb;38(2):201-211. doi: 10.1002/mds.29268. Epub 2022 Nov 7.

Pathomechanisms of depression in multiple system atrophy

Jellinger KA.

J Neural Transm (Vienna). 2023 Jan;130(1):1-6. doi: 10.1007/s00702-022-02560-y. Epub 2022 Nov 8.

Subjective Cognitive Complaints in Cognitively Normal Patients With Parkinson's Disease: A Systematic Review

Hong JY, Lee PH.

J Mov Disord. 2023 Jan;16(1):1-12. doi: 10.14802/jmd.22059. Epub 2022 Nov 10.

Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseases

Ryman S, Vakhtin AA, Richardson SP, Lin HC.

J Neurol. 2023 Feb;270(2):746-758. doi: 10.1007/s00415-022-11461-9. Epub 2022 Nov 10.

Ayahuasca's therapeutic potential: What we know - and what not

Maia LO, Daldegan-Bueno D, Wießner I, Araujo DB, Tófoli LF.

Eur Neuropsychopharmacol. 2023 Jan;66:45-61. doi: 10.1016/j.euroneuro.2022.10.008. Epub 2022 Nov 8.

Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases

Teixeira MI, Lopes CM, Amaral MH, Costa PC.

Colloids Surf B Biointerfaces. 2023 Jan;221:112999. doi: 10.1016/j.colsurfb.2022.112999. Epub 2022 Nov 2.

Swallowing outcomes in dysphagia interventions in Parkinson's disease: a scoping review

Hirschwald J, Hofacker J, Duncan S, Walshe M.

BMJ Evid Based Med. 2023 Apr;28(2):111-118. doi: 10.1136/bmjebm-2022-112082. Epub 2022 Nov 11.

Dietary energy restriction in neurological diseases: what's new?

Zhang B, Huang R, Xu S, He Y, Li J, Wan L, Xiao B, Luo Z.

Eur J Nutr. 2023 Mar;62(2):573-588. doi: 10.1007/s00394-022-03036-1. Epub 2022 Nov 11.

Referral criteria to palliative care for patients with Parkinson's disease: a systematic review

Chen Y, Hou L, Li W, Wang Q, Zhou W, Yang H.

Curr Med Res Opin. 2023 Feb;39(2):267-279. doi: 10.1080/03007995.2022.2146405. Epub 2022 Dec 28.

Interlinked role of ASN, TDP-43 and Miro1 with parkinopathy: Focus on targeted approach against neuropathy in parkinsonism

Panda SP, Prasanth D, Gorla US, Dewanjee S.

Ageing Res Rev. 2023 Jan;83:101783. doi: 10.1016/j.arr.2022.101783. Epub 2022 Nov 9.

Targeting α-synuclein post-translational modifications in Parkinson's disease

Canever JB, Soares ES, de Avelar NCP, Cimarosti HI.

Behav Brain Res. 2023 Feb 15;439:114204. doi: 10.1016/j.bbr.2022.114204. Epub 2022 Nov 11.

Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum

Ferré S, Sarasola LI, Quiroz C, Ciruela F.

Neuropharmacology. 2023 Feb 1;223:109329. doi: 10.1016/j.neuropharm.2022.109329. Epub 2022 Nov 11.

Patterns of polysomnography parameters in 27 neuropsychiatric diseases: an umbrella review

Zhang Y, Ren R, Yang L, Zhang H, Shi Y, Vitiello MV, Sanford LD, Tang X.

Psychol Med. 2023 Jul;53(10):4675-4695. doi: 10.1017/S0033291722001581. Epub 2022 Nov 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias